Keyword: University College London
Syncona committed £85 million to Freeline, maintaining a big stake in a biotech that aims to redefine treatment of hemophilia B and Fabry disease.
The transatlantic biotech is initially targeting inherited retinal diseases with therapies designed to halt vision loss.
The aim is to apply Synpromics’ synthetic promoter expertise to the development of gene therapies against diseases affecting the blood.
The pact will see UCL work with Synpromics on synthetic gene promoters that enable highly specific gene therapies.
An approved diabetes drug may change the progression of Parkinson's disease rather than just treating symptoms while the disease worsens.
Cell Medica has bought Catapult Therapy TCR for its clinical-phase WT1 T-cell receptor cell therapy.
Cell Medica has raised £60 million ($74 million) to expand its clinical pipeline of cancer cellular immunotherapies.
University College London scientists have identified the inhibitor of a cell-protecting protein as a promising new target in treating Alzheimer’s disease.
Cancer Research UK and London investment firm Syncona have joined forces to fund and launch a new neoantigen-focused lung cancer biotech.
Just two months after signing a CAR-T deal with Baylor, London-based Cell Medica has penned a new pact with University College London (UCL) to use its T-cell tech to help create new, cutting-edge meds for cancer.